



11th April, 2023

The Secretary,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001
Scrip Code: 500674

The Secretary,
The National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza
Bandra-Kurla Complex
Bandra East, Mumbai - 400 050
Symbol: SANOFI

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure) Regulations (LODR) and Company's Policy of determination of Materiality of Events under Regulation 30 of LODR

Dear Sirs / Madam,

We refer to our letter dated 16th September 2022, wherein we had informed that the Ministry of Health and Family Welfare, Government of India, had released the revised National List of Essential Medicines (NLEM), 2022 which include Company's product insulin glargine (100 IU/ml) as part of the said list and subsequently the National Pharmaceutical Pricing Authority (NPPA) will fix the ceiling price for the cost to patients of the products included in the list.

In this regard, we wish to inform you that NPPA has now issued the list to fix the ceiling price for the cost to patients of our Company's insulin glargine brand Lantus® and accordingly the said product will be subject to a price reduction of approx. 21% on a weighted average basis considering the different SKU's being marketed by the Company.

While there will be an impact on sales, the Company does not expect a material impact on the profitability considering the arms-length operating model principle being followed with regard to sourcing of this product from Sanofi Group. The drop in price is also likely to result in some volume traction in Lantus® especially in the second half of the year.

Thanking you,

Yours faithfully
For **Sanofi India Limited**

Radhika Shah
Company Secretary & Compliance Officer
Membership No: A19308